• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

某三级甲等医院内科门诊高血压患者降压药物处方模式的研究

A Study of the Prescription Patterns of Antihypertensive Drugs in Patients Attending the Outpatient Department of Medicine at a Tertiary Care Hospital.

作者信息

Shankpal Pramod D, Lohi Samiksha M, Karande Shilpa, Bonde Vishal N

机构信息

Pharmacology, Topiwala National Medical College & Bai Yamunabai Laxman Nair Charitable Hospital, Mumbai, IND.

Pharmacology, All India Institute of Medical Sciences, Nagpur, IND.

出版信息

Cureus. 2025 Jul 18;17(7):e88270. doi: 10.7759/cureus.88270. eCollection 2025 Jul.

DOI:10.7759/cureus.88270
PMID:40831879
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12358638/
Abstract

Background Hypertension is a major global public health concern and a leading risk factor for cardiovascular, cerebrovascular, and renal diseases. Despite the availability of evidence-based guidelines for hypertension management, discrepancies often exist between recommended practices and real-world prescribing patterns. This study aimed to evaluate the prescription pattern of antihypertensive drugs in patients attending the outpatient department (OPD) of medicine at a tertiary care hospital and to assess the adherence of prescribed therapies to the Eighth Joint National Committee (JNC 8) guidelines. Methods This was a cross-sectional, single-center, observational study conducted over two years, with data collection spanning six months (April to September 2023) in the OPD of medicine of a tertiary care hospital. A total of 334 patients diagnosed with primary hypertension, meeting the inclusion criteria, were enrolled after obtaining informed consent. Data were collected from printed hospital management information system (HMIS)-generated prescriptions, which included diagnosis, past history, and antihypertensive treatment, along with patient interviews. Data regarding demographics, comorbidities, and antihypertensive prescriptions were collected and analyzed. Prescriptions were also evaluated for adherence to JNC 8 guidelines. Results Among 334 patients, 182 (54.49%) were male and 152 (45.51%) were female, with a mean age of 57.2 ± 11.39 years. The majority (57.49%) belonged to the 40-60 years age group. A total of 536 antihypertensive drugs were prescribed, with an average of 1.60 ± 0.65 drugs per prescription. Among the 334 prescriptions analyzed, calcium channel blockers (CCBs) were the most commonly prescribed class (76.95%), followed by angiotensin receptor blockers (ARBs) (60.18%), diuretics (27.25%), beta-blockers (BBs) (18.26%), angiotensin-converting enzyme inhibitors (ACEIs) (5.99%), and alpha-blockers (0.6%). Monotherapy was prescribed in 36.23% of cases, while 63.77% received combination therapy, with two-drug combinations being most common (41.62%). Among monotherapy prescriptions, CCBs were preferred (71.9%), followed by ARBs (20.66%). The most frequent two-drug combination was CCB + ARB (61.87%), while the three-drug combination of CCB + ARB + diuretic was most common (60.66%). In four-drug combinations, CCB + ARB + BB + diuretic was most frequently used (76.93%). Comorbidities were present in 52.69% of patients, with diabetes mellitus (68.18%) being the most prevalent. In diabetic hypertensive patients, CCBs (80.83%) were most commonly prescribed; 82.63% of prescriptions adhered to JNC 8 guidelines. Conclusion The study revealed a high prevalence of CCB and ARB use, both as monotherapy and combination therapy, in accordance with national and international guidelines. However, prescribing trends were influenced by factors such as physician preference, comorbidities, and individual clinical judgment. Regular prescription audits and awareness programs focusing on evidence-based guidelines are essential to ensure rational antihypertensive drug use and optimal patient outcomes.

摘要

背景

高血压是全球主要的公共卫生问题,也是心血管、脑血管和肾脏疾病的主要危险因素。尽管有基于证据的高血压管理指南,但推荐做法与实际处方模式之间往往存在差异。本研究旨在评估一家三级医院内科门诊患者的降压药物处方模式,并评估所开治疗方案对美国国家联合委员会第八版(JNC 8)指南的依从性。

方法

这是一项为期两年的横断面、单中心观察性研究,数据收集涵盖一家三级医院内科门诊六个月(2023年4月至9月)的时间。在获得知情同意后,共纳入334例符合纳入标准的原发性高血压患者。数据从医院管理信息系统(HMIS)生成的打印处方中收集,其中包括诊断、既往病史和降压治疗情况,同时还进行了患者访谈。收集并分析了有关人口统计学、合并症和降压处方的数据。还评估了处方对JNC 8指南的依从性。

结果

在334例患者中,男性182例(54.49%),女性152例(45.51%),平均年龄为57.2±11.39岁。大多数(57.49%)属于40 - 60岁年龄组。共开出536种降压药物,平均每张处方1.60±0.65种药物。在分析的334张处方中,钙通道阻滞剂(CCB)是最常用的类别(76.95%),其次是血管紧张素受体阻滞剂(ARB)(60.18%)、利尿剂(27.25%)、β受体阻滞剂(BB)(18.26%)、血管紧张素转换酶抑制剂(ACEI)(5.99%)和α受体阻滞剂(0.6%)。36.23%的病例采用单药治疗,而63.77%接受联合治疗,其中两药联合最为常见(41.62%)。在单药治疗处方中,CCB最为常用(71.9%),其次是ARB(20.66%)。最常见的两药联合是CCB + ARB(61.87%),而CCB + ARB + 利尿剂的三药联合最为常见(60.66%)。在四药联合中,CCB + ARB + BB + 利尿剂使用最为频繁(76.93%)。52.69%的患者存在合并症,其中糖尿病最为常见(68.18%)。在糖尿病高血压患者中,CCB是最常用的药物(80.83%);82.63%的处方符合JNC 8指南。

结论

该研究表明,根据国家和国际指南,CCB和ARB无论是作为单药治疗还是联合治疗都有很高的使用率。然而,处方趋势受到医生偏好、合并症和个体临床判断等因素的影响。定期进行处方审核以及开展以循证指南为重点的宣传项目对于确保合理使用降压药物和实现最佳患者治疗效果至关重要。

相似文献

1
A Study of the Prescription Patterns of Antihypertensive Drugs in Patients Attending the Outpatient Department of Medicine at a Tertiary Care Hospital.某三级甲等医院内科门诊高血压患者降压药物处方模式的研究
Cureus. 2025 Jul 18;17(7):e88270. doi: 10.7759/cureus.88270. eCollection 2025 Jul.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Pharmacological interventions for hypertension in children.儿童高血压的药物治疗干预措施。
Cochrane Database Syst Rev. 2014 Feb 1;2014(2):CD008117. doi: 10.1002/14651858.CD008117.pub2.
4
Cochrane in context: pharmacological interventions for hypertension in children.Cochrane背景下:儿童高血压的药物干预
Evid Based Child Health. 2014 Sep;9(3):581-3. doi: 10.1002/ebch.1975.
5
Pharmacological interventions for hypertension in children.儿童高血压的药物干预措施。
Evid Based Child Health. 2014 Sep;9(3):498-580. doi: 10.1002/ebch.1974.
6
Beta-blockers for hypertension.用于治疗高血压的β受体阻滞剂。
Cochrane Database Syst Rev. 2007 Jan 24(1):CD002003. doi: 10.1002/14651858.CD002003.pub2.
7
ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.血管紧张素转换酶抑制剂对非透析慢性肾脏病 3-5 期患者的肾脏和心血管结局的益处:随机临床试验的网络荟萃分析。
Drugs. 2020 Jun;80(8):797-811. doi: 10.1007/s40265-020-01290-3.
8
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
9
Beta-blockers for hypertension.用于治疗高血压的β受体阻滞剂。
Cochrane Database Syst Rev. 2017 Jan 20;1(1):CD002003. doi: 10.1002/14651858.CD002003.pub5.
10
Prescribing Trends for Bipolar Disorder Drugs in Alberta, Canada Between 2008 and 2021: Tendances en matière de prescription de médicaments pour le trouble bipolaire en Alberta, au Canada, entre 2008 et 2021.2008年至2021年加拿大艾伯塔省双相情感障碍药物的处方趋势:2008年至2021年加拿大艾伯塔省双相情感障碍药物的处方趋势。
Can J Psychiatry. 2025 Jul 10:7067437251355643. doi: 10.1177/07067437251355643.

本文引用的文献

1
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).2023ESH 动脉高血压管理指南 欧洲高血压学会动脉高血压管理工作组:得到国际高血压学会 (ISH) 和欧洲肾脏协会 (ERA) 的认可。
J Hypertens. 2023 Dec 1;41(12):1874-2071. doi: 10.1097/HJH.0000000000003480. Epub 2023 Sep 26.
2
2020 International Society of Hypertension Global Hypertension Practice Guidelines.2020年国际高血压学会全球高血压实践指南
Hypertension. 2020 Jun;75(6):1334-1357. doi: 10.1161/HYPERTENSIONAHA.120.15026. Epub 2020 May 6.
3
Hypertension in older adults: Assessment, management, and challenges.老年人高血压:评估、管理与挑战。
Clin Cardiol. 2020 Feb;43(2):99-107. doi: 10.1002/clc.23303. Epub 2019 Dec 11.
4
Prescribing pattern of antihypertensive medication and adherence to Joint National Commission-8 guidelines in a rural tertiary care Indian teaching hospital.印度一家农村三级护理教学医院的抗高血压药物处方模式及对美国国家联合委员会第8版指南的依从性
J Basic Clin Physiol Pharmacol. 2019 Sep 10;31(1):jbcpp-2019-0133. doi: 10.1515/jbcpp-2019-0133.
5
Management of Hypertension in Chronic Kidney Disease.高血压合并慢性肾脏病的管理。
Drugs. 2019 Mar;79(4):365-379. doi: 10.1007/s40265-019-1064-1.
6
2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).2014 年成人高血压管理的循证指南:第八届联合国家委员会(JNC 8)任命的专家组报告。
JAMA. 2014 Feb 5;311(5):507-20. doi: 10.1001/jama.2013.284427.
7
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes.盎格鲁-斯堪的纳维亚心脏结局试验:降压组:对2型糖尿病患者的影响。
J Hypertens. 2008 Nov;26(11):2103-11. doi: 10.1097/HJH.0b013e328310e0d9.
8
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).高危高血压患者随机接受血管紧张素转换酶抑制剂或钙通道阻滞剂与利尿剂治疗的主要结局:抗高血压和降脂治疗预防心脏病发作试验(ALLHAT)
JAMA. 2002 Dec 18;288(23):2981-97. doi: 10.1001/jama.288.23.2981.
9
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.血压降低及抗高血压药物类别对高血压肾病进展的影响:AASK试验结果
JAMA. 2002 Nov 20;288(19):2421-31. doi: 10.1001/jama.288.19.2421.